Improving Adherence in HIV Treatment with Once-Daily Therapies
Switching from first ART regimen while virologically suppressed is common in the CANOC cohort and is associated with increased risk of subsequent virologic.
When to Start When to Stop? What to Start? Joseph J. Eron, Jr, MD Professor of Medicine Principal Investigator AIDS Clinical Trials Unit School of Medicine.
New Therapeutic Agents and Treatment Guidelines
M Hull, A Cescon, JM Raboud, MB Klein , S Walmsley,
